University of Tennessee Health Science Center

RevBio Receives NIH Grant to Explore the Treatment of Vertebral Compression Fractures with Its Regenerative Bone Adhesive Technology

Retrieved on: 
Tuesday, September 20, 2022
Biotechnology, FDA, Professional Services, Other Health, Health, General Health, Small Business, Neurology, Health Technology, Medical Devices, Clinical Trials, University of Tennessee Health Science Center, National, Vertebral compression fracture, Biomedicine, Vertebra, Embolism, Medicare, Risk, Microdeletion syndrome, Prevalence, Biomedical engineering, Ageing, Innovation, National Institute on Aging, PMMA, Augmented fifth, Fracture, Fluoroscopy, CEO, Technology, SBIR, Dentistry, Research, Orthopedic surgery, Multimedia, University, National Institute, Pharmaceutical industry, Medical imaging, Neurosurgery

This funding will allow the company to pursue the treatment of vertebral compression fractures with its patented bone adhesive technology known as Tetranite.

Key Points: 
  • This funding will allow the company to pursue the treatment of vertebral compression fractures with its patented bone adhesive technology known as Tetranite.
  • View the full release here: https://www.businesswire.com/news/home/20220920005501/en/
    Pre-clinical testing of the percutaneous injection of TETRANITE to treat a vertebral compression fracture.
  • This regenerative, adhesive, and cohesive material delivered percutaneously could significantly improve the way these fractures are treated.
  • In the United States, approximately 700,000 vertebral compression fractures (VCF) occur each year, costing an estimated $250 million in Medicare-related expenses.

The Foundation for Sickle Cell Disease Research Hosts Virtual Symposium Highlighting the Applications of Machine Learning in Sickle Cell

Retrieved on: 
Thursday, September 15, 2022
University of Tennessee Health Science Center, Adoption, VP, Therapy, Symposium, Machine learning, Center, CME, UTHSC, Manifest and latent functions and dysfunctions, Learning, Social media, COO, Patient, Sickle cell disease, Intelligence, Physician, SCD, Technology, Solution, Informatics, Foundation, Research, Acute chest syndrome, University, Health informatics, Science, Medical device, Pharmaceutical industry

FORT LAUDERDALE, Fla., Sept. 15, 2022 /PRNewswire/ -- On September 22nd, during Sickle Cell Awareness Month, The Foundation for Sickle Cell Disease Research (FSCDR), the US's first outpatient center exclusively dedicated to the treatment of and innovative research for SCD, will host a one-day virtual symposium on featured topic: the Applications of Machine Learning in Sickle Cell.

Key Points: 
  • FORT LAUDERDALE, Fla., Sept. 15, 2022 /PRNewswire/ -- On September 22nd, during Sickle Cell Awareness Month, The Foundation for Sickle Cell Disease Research (FSCDR), the US's first outpatient center exclusively dedicated to the treatment of and innovative research for SCD, will host a one-day virtual symposium on featured topic: the Applications of Machine Learning in Sickle Cell .
  • They all share the common goal of finding better treatment, and ultimately, a cure for sickle cell disease by exploring and learning about the future of artificial intelligence and technology in healthcare.
  • Sickle cell warriors and their caretakers are invited to participate in the symposium at no cost.
  • We are hopeful that machine learning is one of many tools that offer life-saving solutions to patients in the future."

Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Tennessee Health Science Center to Investigate Pharmaceutical-Grade Rose Bengal as Anti-Fungal and Anti-Oral Bacterial Agent

Retrieved on: 
Wednesday, August 24, 2022
National, Xanthene, University, Security (finance), Gram-negative bacteria, Safety, Gram-positive bacteria, Biofilm, Ophthalmology, Research, Legislation, RBS, College, Virology, Doctor of Philosophy, Hematology, Convoy HX 156, Department, Forward-looking statement, SEC, NIH, U.S. Securities and Exchange Commission, HX, P.O, Manuscript, Pharmacy, Molecule, GLOBE, Company, Immunotherapy, Dye, IL, University of Tennessee Health Science Center, Drug discovery, Dermatology, Microbiology, OTCQB, UTHSC, Pharmaceutical industry, Narumi Kurosu

Provectus innovatively-assembled and proprietary rose bengal is the lead member of a class of the Companys small molecules called halogenated xanthenes.

Key Points: 
  • Provectus innovatively-assembled and proprietary rose bengal is the lead member of a class of the Companys small molecules called halogenated xanthenes.
  • As part of this new sponsored research, the Kurosu team plans to evaluate the in vitro activity of Provectus rose bengal against different fungal strains and to conduct susceptibility tests against fungal and bacterial mouth microbes.
  • These data and conclusions were noted in Kurosu et al.s 2022 Molecules article entitled Antibacterial Activity of Pharmaceutical-Grade Rose Bengal: An Application of a Synthetic Dye in Antibacterial Therapies .
  • The Kurosu team is currently developing a journal manuscript of their prior study of the molecules in vitro activity against Gram-negative bacteria.

AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF ZONISADE™ (zonisamide oral suspension)

Retrieved on: 
Monday, July 18, 2022
University, University of Tennessee Health Science Center, CEO, Patient, Awareness, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neurology, Association, Safety, Epilepsy, Depression, Azure Transit Connect Electric, Food, Zonisamide, United, Chair, Anxiety, Endocrinology, Caregiver burden, Brain, Pediatric Neurology, Multimedia, Tablet, Industry, Autism, Ageing, FDA, Learning, Pharmaceutical industry

WOBURN, Mass., July 18, 2022 /PRNewswire/ -- Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked patients, today announced the U.S. Food and Drug Administration (FDA) approval of ZONISADE™ (zonisamide oral suspension),

Key Points: 
  • "ZONISADE is the first and only FDA-approved oral liquid formulation of zonisamide, and it offers healthcare providers an important new treatment option for their patients with epilepsy," said Richard Blackburn, CEO of Azurity Pharmaceuticals.
  • "We are excited about this approval as we continue to grow our portfolio of liquid medications that meet the individual needs of certain patients."
  • "ZONISADE addresses an important unmet need in patients who have difficulty swallowing or who are unable or unwilling to take tablets."
  • "The FDA approval and availability of ZONISADE is a welcomed advancement for patients and their families who may be seeking a liquid formulation alternative to treat epilepsy."

Sourabh Mukherjee, MD is recognized by Continental Who's Who

Retrieved on: 
Tuesday, June 28, 2022
Vascular surgery, Morehouse School of Medicine, Fellowship of the Royal Colleges of Surgeons, Medical degree, Society for Vascular Surgery, Patient, Life, Continental, Indian Medical Association, Elective surgery, Varicose veins, American Board of Surgery, Society, Medicine, University of Tennessee Health Science Center, University, Learning, Blood, Family, American College, Disease, Physician, American Medical Association, American Board of Commissioners for Foreign Missions, MD, Multimedia, General surgery, Dentistry

HATTIESBURG, Miss., June 28, 2022 /PRNewswire/ -- Sourabh Mukherjee, MD, is being recognized by Continental Who's Who as a Top Healthcare Professional for his distinguished career in Vascular Surgery and in acknowledgment of his work with Hattiesburg Clinic Vascular Specialists.

Key Points: 
  • HATTIESBURG, Miss., June 28, 2022 /PRNewswire/ -- Sourabh Mukherjee, MD, is being recognized by Continental Who's Who as a Top Healthcare Professional for his distinguished career in Vascular Surgery and in acknowledgment of his work with Hattiesburg Clinic Vascular Specialists.
  • In his practice, he utilizes a combination of therapies, including minimally invasive outpatient procedures and open surgery, depending on the patient's individual medical needs.
  • He completed a Residency in General Surgery and a Fellowship in Vascular Surgery at the University of Tennessee Health Science Center.
  • Dr. Mukherjee is an active member of the American Medical Association and the Society for Vascular Surgery, among his professional affiliations.

Anheuser-Busch Foundation and UNCF Renew Partnership to Provide Emergency Aid to Help HBCU Students Achieve College Degrees

Retrieved on: 
Monday, June 6, 2022
Faculty, Student, Biology, Friends, Curriculum, Economic development, Â, UNCF, Anheuser family, LeMoyne–Owen College, University of Tennessee Health Science Center, Allen University, Partnership, News, Anheuser-Busch, Mentorship, Organization, Investment, University, Historically black colleges and universities, GLOBE, Twitter, Engineering, Drinking, Benedict College, Foundation, Education, Tutoring, Medicine, Beer, HBCU

Recently for some, their dream would have been shattered had it not been for emergency funding assistance from UNCF (United Negro College Fund) provided by the Anheuser-Busch Foundation.

Key Points: 
  • Recently for some, their dream would have been shattered had it not been for emergency funding assistance from UNCF (United Negro College Fund) provided by the Anheuser-Busch Foundation.
  • Through last years grant, 69 students received assistance this year to help them walk across the stage on graduation day.
  • We thank the Anheuser-Busch Foundation for helping these talented, deserving students to realize their college graduation and make their dreams come true.
  • Scholarship recipients have shared thank you videos , expressing their appreciation to UNCF and Anheuser-Busch Foundation for providing the emergency funds necessary to help them graduate.

RedHill Presents New Talicia® Data Analyses at DDW 2022

Retrieved on: 
Wednesday, May 25, 2022
Diabetes, ITT, Risk, Redhill, Population, Doctor of Philosophy, TEL, World, DDW, Amoxicillin, Food, Patient, HP, World Health Organization, NASDAQ, Genetically modified bacteria, PBPK, Stomach, Adult, DM, FDA, Mitt, Helicobacter pylori, University of Tennessee Health Science Center, Metronidazole, WHO, Arthouse at The Jones Center, MALT, Ulcerative colitis, ACG, Safety, University, Maintenance, QD, PPI, Omeprazole, Rifabutin, Diarrhea, Clarithromycin, Pharmaceutical industry, Vaccine, MD

RALEIGH, N.C. and TEL AVIV, Israel, May 25, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the presentation of two new data analyses from the Talicia®H. pylori eradication clinical trials program at Digestive Diseases Week (DDW) 2022.

Key Points: 
  • pylori eradication clinical trials program at Digestive Diseases Week (DDW) 2022.
  • "More than 37 million Americans have diabetes, which presents significant issues in the treatment of H. pylori infection.
  • "Talicia consistently shows its ability to maintain high H. pylorieradication rates, even in challenging patient populations, with zero to minimal resistance.
  • In November 2019, Talicia was approved by the U.S. FDA for the treatment of H. pylori infection in adults.

University of Tennessee Health Science Center Leverages CareCloud’s Technology to Enhance Revenues and Streamline Workflows

Retrieved on: 
Monday, May 9, 2022
Practice management, EHR, CareCloud, University, Department, Record, Health, RFP, GLOBE, Dentistry, Oral, Organization, University of Tennessee, Pathology, RCM, University of Tennessee Health Science Center, PXM, Solution, MTBC, Health information management, Biopsy, Collection

SOMERSET, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: MTBC, MTBCO, MTBCP), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced that the University of Tennessee Health Science Center, College of Dentistry Pathology, has selected CareClouds Revenue Cycle Services and talkEHR to enhance revenues, streamline workflows, and alleviate billing inefficiencies.

Key Points: 
  • SOMERSET, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: MTBC, MTBCO, MTBCP), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced that the University of Tennessee Health Science Center, College of Dentistry Pathology, has selected CareClouds Revenue Cycle Services and talkEHR to enhance revenues, streamline workflows, and alleviate billing inefficiencies.
  • The University of Tennessee is the seventh university specializing in oral pathology to select CareClouds cloud-based technology and the second university to select CareCloud this month.
  • We look forward to helping the University of Tennessee increase profitability with our digital, secure and flexible billing and EHR system, said Al Nardi SVP Strategy, CareCloud.
  • CareCloud will also enable the University of Tennessee to streamline workflows and enhance patient experiences within OMDS by digitizing records and migrating to talkEHRs integrated practice management system.

Accelus Appoints Kevin Foley, MD as Chief Robotics Officer

Retrieved on: 
Monday, April 18, 2022
Awareness, Adoption, Robotics, Baptist Memorial Hospital-Memphis, MD, Medicine, 3D ultrasound, Hospital, GLOBE, Spine, Cranial nerves, OR, Efficiency, Surgeon, Technology, PALM, CRO, Safety, University of Tennessee Health Science Center, BEACH, Neurosurgery, Fusion, MIS, University, Biomedical engineering, Surveying, Medical device, 3D printing

PALM BEACH GARDENS, Fla., April 18, 2022 (GLOBE NEWSWIRE) -- Accelus, a privately held medical technology company focused on accelerating the adoption of minimally invasive surgery (MIS) as the standard of care in spine, today announced the appointment of Kevin Foley, MD, as the Companys first Chief Robotics Officer (CRO).

Key Points: 
  • PALM BEACH GARDENS, Fla., April 18, 2022 (GLOBE NEWSWIRE) -- Accelus, a privately held medical technology company focused on accelerating the adoption of minimally invasive surgery (MIS) as the standard of care in spine, today announced the appointment of Kevin Foley, MD, as the Companys first Chief Robotics Officer (CRO).
  • Accurate screw placement is a critical step in spine surgery, as misplaced screws can injure the surrounding spinal nerves and cause increased patient pain.
  • Dr. Foley has spent decades working to improve the safety, efficiency, and accuracy of spine surgery with the use of computerized-image guidance.
  • Accelus is committed to accelerating minimally invasive spine surgery through its enabling technology with broad accessibility to previously underserved markets.

Ariste Medical Receives FDA 510(k) Clearance For New Drug-Embedded Mesh to Reduce Risk of Microbial Colonization Following Hernia Repair

Retrieved on: 
Tuesday, April 5, 2022
Risk, University, DRS, University of Tennessee Health Science Center, UTHSC, Thrombosis, Rifampicin, Board, Bacteria, Research, Biotechnology, Faculty, Incidence, Medical director, Food, Escherichia coli, Restenosis, Catheter, Hernia, SALT, Quality of life, Technology, Inflammation, Surgeon, Regulation of tobacco by the U.S. Food and Drug Administration, Disease, Infection, FDA, Minocycline, MRSA, Subclinical infection, Patient, Antibiotics, Medical device, Pharmaceutical industry, Ariste

SALT LAKE CITY, April 5, 2022 /PRNewswire-PRWeb/ -- Ariste Medical, a pre-commercial drug+device company, today announced it has received 510(k) clearance (#K211132) from the U.S. Food and Drug Administration (FDA) to market its drug-embedded, synthetic hernia mesh in the United States. The new mesh aims to reduce the risk of microbial colonization during surgical implantation.

Key Points: 
  • The new mesh aims to reduce the risk of microbial colonization during surgical implantation.
  • Mesh-related infection following surgical repair of ventral hernia can range from 8%-40%, depending on patient risk factors and the complexity of the surgical case.
  • "Regulatory clearance of the Ariste antibiotic embedded mesh is an important milestone toward reducing incidence of implant bacterial colonization in open ventral hernia repair," said Dr. Lisa Jennings, co-founder of Ariste.
  • Ariste Medical develops drug-embedded surgical implants to address common causes of device failure, improve patient outcomes and reduce costs of care.